Cardiac Wire #159 March 14, 2024
Wegovy’s CVD Expansion | Painting Away Blockages
Cardiac Wire #158 March 11, 2024
Plastics in Our Plaque | Tendyne’s TMVR Promise
Cardiac Wire #157 March 7, 2024
PROACTIVE’s HF Impact | CAD Breakthrough
Cardiac Wire #156 March 4, 2024
First DCB Approval | Low-Risk ECGs
Cardiac Wire #155 February 29, 2024
Lipoprotein(a)’s CV Risk Thresholds | Intravascular Imaging’s PCI Advantage
Cardiac Wire #154 February 26, 2024
Radiation-Free Interventions | High Protein and CVD
Cardiac Wire #153 February 22, 2024
Transforming ADHF Decongestion | Lp(a)’s Independent Risks
Cardiac Wire #152 February 15, 2024
Big TEER Vote | HDL Theory Fails Again
Cardiac Wire #151 February 12, 2024
Bypass Surgery’s Hypertension Impact | Too Big for Donor Hearts
Cardiac Wire #150 February 8, 2024
Biosense Webster’s PFA Evidence | Zepbound’s Boundless Potential
Cardiac Wire #149 February 5, 2024
First TR Treatment | HCM’s TV Moment
Cardiac Wire #148 February 1, 2024
SAVR’s Outcomes vs. TAVR Adoption | Heart Disease Unawareness
Cardiac Wire #147 January 29, 2024
Vascepa’s ACS Advantage | Stopping the Bleed
Cardiac Wire #146 January 25, 2024
Smartphone CVD Detection | Sitting’s Cardiovascular Risks
Cardiac Wire #145 January 22, 2024
Lipoprotein(a)’s Per-Particle Risks | PFA Haemolysis
Cardiac Wire #144 January 18, 2024
Private Equity’s Cardiology Impact | Echo AI for RHD
Cardiac Wire #143 January 11, 2024
Faster Heart Failure GDMT Optimization | Cleerly ISCHEMIA
Cardiac Wire #142 January 8, 2024
Applied AT-001’s Phase 3 Miss | Lilly Does DTC
Cardiac Wire #141 January 4, 2024
